2025 Silent Capital Report now available. Where family offices and LPs are actually deploying. [Download for free →]
About usSign in
Status
ACTIVE
Global HQ
Boston, United States
Countries of investment
  • United States
  • United Kingdom
  • Germany
  • Switzerland
  • Netherlands
  • Israel
Investment stages
  • Pre-Seed
  • Seed
  • Series A
  • Series B
  • Series C
  • Growth
Industries
  • Biotech
  • Healthcare
About
Omega Funds is a leading international investment firm that creates and invests in life sciences companies targeting the world's most urgent medical needs. They position themselves as hands-on, science-driven partners to entrepreneurs and scientists, supporting companies from inception through to public markets.
Min check size
$100K
Max check size
$1M
Fund size
NPS

Investment Thesis

Omega Funds is a specialized life sciences investment firm focusing on companies addressing urgent medical needs. They invest across all stages, from company creation and early-stage ventures to late-stage and public companies, primarily in North America and Europe. Their unique approach combines deep scientific expertise with a hands-on, collaborative model to build and support transformative healthcare companies from inception to exit.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

The management team comprises seasoned professionals with extensive backgrounds in both life sciences investment and corporate operations. Key partners have held senior leadership roles at major pharmaceutical companies like GSK, Sanofi, and Vertex, as well as other prominent venture firms including Index Ventures and Abingworth. This unique combination of scientific, R&D, corporate development, and venture capital expertise underpins their strategy of building and investing in innovative biotech companies.

Omega Funds Contacts Information

Primary contact

Secondary contact

Team

Otello Stampacchia - Founder and Managing Director

Michelle Doig - Managing Director

Bernard Davitian - Partner

Paul-Peter Tak - Partner

Francesco Draetta - Partner

Dina Ciarimboli - Partner & General Counsel

Vincent Ossipow - Partner

Portfolio

Adagio Therapeutics

Arcutis Biotherapeutics

Corvus Pharmaceuticals

Editas Medicine

Gossamer Bio

Ikena Oncology

Nuvation Bio

Prevail Therapeutics

Replimune

Theseus Pharmaceuticals

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp